-
Spurs boss De Zerbi targets one more big signing before window shuts
-
Meta's teen safety deal runs into an unsolved problem: proving age
-
Fed chair Warsh flags high US inflation as 'concerning'
-
Windmills of change: Dutch raise mill in rare operation
-
Same Election Question, Two Different Odds: Predictions.io Launches Free Cross-Venue Comparison Tools
-
Netanyahu party in uproar as far-right refuses pleas to unite
-
Man Utd new signing Baleba sidelined for three weeks
-
Stocks advance with all eyes on Fed chair's speech
-
Juve's Yildiz to miss 'several months' with foot injury
-
War criminal Ratko Mladic's death lays bare Bosnia's wounds
-
Celine Dion arrives in France ahead of sold-out comeback dates
-
Thieves buy tickets before plundering necklace from Vienna museum
-
All-round Tongue stars for England in second Test against Pakistan
-
Swiss nuclear plant fully back online after heatwaves
-
UEFA's legal move 'massive escalation' in bitter Infantino feud
-
Bournemouth, Sunderland to face AC Milan in Europa League
-
MEXC Launches Earn Plus With Limited-Time Event Offering Up to 800% APR Booster
-
Once a legend, humpback whales make comeback in Brazil
-
Norway's new King Haakon VIII, popular face of shaken monarchy
-
'Ran for our lives': Tales of survival from Nepal-China disaster
-
Stocks rise ahead of Fed chair's policy speech
-
Bombay High Court Questions Police Probe in Disha Salian Death Case
-
Norway's new King Haakon VII, popular face of shaken monarchy
-
Orthopaedician Dr Akhil Kulshreshtha Shares 5 Tips for Bone and Joint Health
-
Last-wicket duo take England to 290 all out in 2nd Test against Pakistan
-
All eyes on Warsh as Fed chair kicks off key central banking meeting
-
MPSC Drug Inspector Exam Leak: Rutuja Patil Allegedly Paid Rs 50 Lakh for Leaked Paper
-
ONE App Launches AI Agent and Custom GPT to Enhance Digital Banking
-
Japan spent record $96 bn in yen interventions: ministry
-
Indonesia escalates battle against fires, putrid haze
-
Nepal-China floods disaster: Latest developments
-
Germany could miss climate goal in 2026 for first time: think tank
-
Duplantis needs A-game to fend off Karalis pressure
-
New flood risks impede Nepal, Tibet rescue
-
Architect Minenhle Makhanya Ordered to Repay R147 Million for Nkandla Upgrades
-
Kolbe back as Springboks change two for All Blacks Test
-
Iran says still open to diplomacy as war with US hits six months
-
Europe's monarchs, world leaders mourn Norway's King Harald
-
20,000 Salmon Return to Klamath River Following Dam Removal, Yet Recovery Faces Ongoing Challenges
-
Jamie Vardy channel to broadcast Bundesliga games
-
King Harald, 'symbol' of Norway, dead at 89
-
STARCARES Completes Basketball Court Revamp in the Philippines, Benefiting Nearly 20,000 People
-
Norway's new King Haakon, popular face of shaken monarchy
-
Norway's new Queen Mette-Marit, a fairytale beset by woe
-
Most stocks rise as attention turns to Warsh speech
-
Nepal orders rescuers to safety as overflow brings new flood risks
-
Japanese rugby U-turns on limits on naturalised players
-
Norway's King Harald V, unifying force who weathered family storms
-
Norway's King Harald dead at 89
-
Australia's McKeown vows to reclaim backstroke world records
Eyeing Trump trade policy shakeup, Eli Lilly to build 4 US factories
US pharmaceutical giant Eli Lilly announced Wednesday that it will build four additional new manufacturing sites in the United States in a committment designed to influence upcoming Trump administration decisions on trade and other issues.
The drugmaker, which is in growth mode thanks partly to the success of anti-obesity drugs Zepbound and Mounjaro, expects to add more than 3,000 jobs at the four sites as it committed to tens of billions of dollars in additional investment.
Chief Executive David Ricks said in a statement the boosted capital spending underscores the company's "optimism about the potential of our pipeline" and determination to "stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future."
The move, announced at a Washington news conference, comes as Trump proceeds with a deluge of tariff actions and proposed tax cut extensions designed to incentivize global companies to invest in the United States. Trump's administration is also undertaking deep job cuts across the US regulatory universe that could affect such processes as the application for new drugs.
The company's press release described Trump's 2017 corporate tax cut as "foundational to Lilly's domestic manufacturing investments," adding that "it is essential that these policies are extended this year."
In an interview with CNBC, Ricks said he would call on the Trump administration to address lengthy permitting times to build new facilities due to onerous requirements of the US Food and Drug Administration.
Ricks also aims to influence the "contours" of Trump's trade policy, saying "it makes no sense to punish companies that are pursuing this agenda with the administration and on behalf of the American people."
Wednesday's announcement will raise Lilly's domestic capital expansion commitment to $50 billion from $23 billion previously committed between 2020 and 2024 to construct or expand sites in the states of North Carolina, Indiana and Wisconsin.
The company is "currently in negotiations with several states and welcomes additional interest by March 12, 2025," said a press release that included a link to express interest online.
Shares of Lilly rose 1.7 percent shortly after midday.
P.Keller--VB